BridgeBio Pharma, Inc. (NASDAQ: BBIO) reported insider sales by Chief Executive Kumar Neil through trusts where he serves as co-trustee, according to a Form 4 filing. The filing shows a total of 70,185 shares of common stock were sold on March 12 and March 13, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales generated proceeds of approximately $5.5 million.
The transactions were executed in several tranches across the two days. On March 12, sales occurred at prices spanning $68.4686 to $70.15. The specific blocks sold that day were:
- 14,337 shares at a weighted average price of $68.4808
- 5,363 shares at $69.3176
- 300 shares at $70.15
- 13,885 shares at $68.4686
- 5,815 shares at $69.2913
- 300 shares at $70.15
On March 13, additional tranches were recorded with the following breakdown:
- 9,690 shares at a weighted average price of $68.3634
- 10,310 shares at $69.1997
- 10,241 shares at $68.3864
- 9,759 shares at $69.2251
Following these dispositions, ownership disclosed in the filing shows the Kumar Haldea Family Irrevocable Trust holding 635,686 shares and the Kumar Haldea Revocable Trust holding 4,438,447 shares. In addition, Kumar Neil directly owns 234,451 shares. The filing notes that the sales were executed pursuant to a Rule 10b5-1 sales plan adopted by Kumar on March 31, 2025.
Market context included in the filing notes that BBIO shares have climbed 115% over the past year, with the stock trading at $71.03 at the time of reporting. An InvestingPro analysis mentioned in the filing indicates the stock remains undervalued relative to its Fair Value and appears on the platform's Most Undervalued list, with deeper research available through the BBIO Pro Research Report.
Separately, the company disclosed optimistic clinical progress for BBP-418. BridgeBio presented interim results from its Phase 3 FORTIFY trial assessing BBP-418 for limb-girdle muscular dystrophy type 2I/R9. The interim data showed that participants treated with BBP-418 completed a 100-meter timed test significantly faster than those who received placebo, with improvements in ambulation observed early in the study. Based on these results, the company announced plans to submit BBP-418 for regulatory approval and is aiming for a potential launch in late 2026 or early 2027.
Analyst coverage following the clinical update was active. Leerink Partners reiterated an Outperform rating on BridgeBio with a price target of $98. Barclays maintained an Overweight rating and a $157 price target, citing a favorable outcome in Pfizer's tafamidis intellectual property trial. William Blair initiated coverage of BridgeBio with an Outperform rating and a fair value estimate of $93.03 per share, highlighting the company’s accelerating drug launch plans.
Taken together, the insider sales, the company's clinical progress and subsequent analyst activity mark a period of notable corporate and market developments for BridgeBio Pharma. The Form 4 filing confirms the timing, tranche-level detail and the governance mechanism - a Rule 10b5-1 plan - that governed the CEO's sales executed in March 2026.